# RTOG-1106 (NCT01507428)

> Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: none (the trial tests a strategy, not a drug)
- Indication: stage III non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01507428
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: National Cancer Institute (NCI)
- Conditions: Stage III Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Interventions: 18F-Fluoromisonidazole; Carboplatin; Computed Tomography; Computed Tomography; External Beam Radiation Therapy; Fludeoxyglucose F-18; Image-Guided Adaptive Radiation Therapy; Laboratory Biomarker Analysis; Paclitaxel; Positron Emission Tomography; Positron Emission Tomography
- Enrollment: 138
- Primary outcome: Percentage of Participants Alive Without Local-regional Progression [Local-regional Progression-free (LRPF) Survival] at Two Years (NRG)
- Primary outcome: Relative Change in SUVpeak From the Baseline to the During-treatment Fludeoxyglucose F 18 (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) to LRPF With a 2-year Follow up. (ECOG-ACRIN)

## Indexed commentary on RTOG-1106 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X
- 2 YouTube videos
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=rtog-1106-nct01507428